Hematologic Oncology

Researchers at North Carolina State University used canines as genetic models for studying lymphomas

Reynaldo Garcia from the UNC Lineberger Comprehensive Cancer Center Explains the BCR-ABL Study

Reynaldo Garcia from the University of North Carolina Lineberger Comprehensive Cancer Center on BCR-ABL Testing in Chronic Myelogenous Leukemia

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

Researchers have sequenced 38 tumor genomes from patients with multiple myeloma (MM), comparing them with normal DNA.

Seattle Genetics, Inc announced on Monday that the FDA has accepted filings for two Biologics License Applications for bretuximab vedotin

The American Society of Hematology (ASH) is sounding a fresh alarm about ongoing supply problems with oncology drugs

The FDA reported today that TNF blockers may be responsible for an increased incidence of HSTCL in adolescents and young adults

The brave, (relatively) new world of social networking has presented even the medical community with challenges, but with a few precautions fellows can avoid some of the pitfalls associated with an online presence.

Genome sequencing may help researchers understand the pathogenesis of this cancer, which despite exhaustive research, is only partially understood

A new tool for mapping disease severity and outcomes in patients with Gaucher disease (GD) may help physicians develop a standardized approach to treatment

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.

Rituximab is a humanized monoclonal antibody that is used for the treatment of a wide variety of B-cell-derived hematologic malignancies

In this role, I hope to help the journal achieve its mission in bringing readers high-quality, peer-reviewed research, provocative commentaries, and personal patient stories.

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on the escalating costs associated with cancer car

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, discusses ongoing myeloma clinical trials in the spring of 2011.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains his thoughts on accelerated drug approvals.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on biomarkers and molecular analysis.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.